Breaking News

Evonik Expands Formulation Capabilities for Lipid Nanoparticles

Collaboration with KNAUER aims to streamline and improve the scale-up of LNP formulations for mRNA and gene therapies.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Evonik is collaborating with KNAUER Wissenschaftliche Geräte GmbH, a manufacturer of scientific instruments, to improve the scale-up of lipid nanoparticle (LNP) formulations. Combining Evonik’s formulation and scale-up expertise with KNAUER’s technological know-how, aims to improve efficiency and increase speed to market, cutting the initial preclinical development time.   Nucleic acid therapeutics represent growing proportion of the overall parental drugs market. Evonik supplies pharmaceutica...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters